---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-018788"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2025-10-21T23:59:59+00:00"
generated_at: "2026-05-17T03:03:56.298456+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma signs $10M term sheet to buy Molecule assets; CRO Theradex terminates, seeks $1.09M

## Summary
- Binding term sheet for $10M purchase of substantially all assets and liabilities of Molecule; consideration in cash and stock per Shuttle's sole discretion, with milestones.
- CRO Theradex terminated Master Agreement on Oct 15, 2025, demanding immediate payment of $1.091M; if unpaid in 30 days, services will cease.
- Theradex is Shuttle's primary CRO; termination threatens clinical trial operations and requires immediate cash payment.
- Transaction subject to due diligence, board approval, definitive agreements; exclusivity period of 90 days from Oct 20, 2025.
- Shuttle intends to retain Molecule's CEO ZT Zhang for post-transaction transition and integration.

## SEC filing metadata
- accession: 0001493152-25-018788
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2025-10-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315225018788/0001493152-25-018788-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315225018788/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-018788
- JSON: https://secwatch.observer/filing/0001493152-25-018788.json
- Plain text: https://secwatch.observer/filing/0001493152-25-018788.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.